POSTER 21

Long-Term Safety and Disease Control of Ruxolitinib Cream in Children Aged 2 to 6 and 7 to 11 Years With Atopic Dermatitis: Results From the TRuE-AD3 Study

Weily Soong, MD; Andrea L. Zaenglein, MD; Megha M. Tollefson, MD; Eric L. Simpson, MD, MCR; Alim R. Devani, MD; Joel C. Joyce, MD; Joel Schlessinger, MD; Dareen D. Siri, MD; Brett Angel, MD; Daniel Sturm, PharmD; Haobo Ren, PhD; Amy S. Paller, MD

< Previous Poster | Next Poster >

Poster 21